Abstract
AbstractWe compare the risks of hospitalization (n=1121) and mortality (n=138) in a cohort of 17,881 breakthrough SARS-CoV-2 infections for the Pfizer, Moderna and Janssen vaccines for those with and without SARS-CoV-2 infections prior to vaccination. Cox regression analysis results in a lower hazard ratio for breakthroughs receiving the Moderna vaccine, but a significantly higher hazard ratio for breakthroughs receiving the Janssen vaccine, as compared to breakthroughs who got the Pfizer vaccine. Further, the risk of hospitalization (P<0.001) and death (P<0.05) were lower among breakthroughs who had a SARS-CoV-2 infection prior to vaccination, independent of age, sex, comorbidities, and vaccine type.NoteWe do not study the role of natural immunity in SARS-CoV-2 infections, as our cohort does not contain unvaccinated individuals.
Publisher
Cold Spring Harbor Laboratory
Reference11 articles.
1. https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status
2. https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination
3. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
4. Uschner, D. , Bott, M. , Santacatterina, M. , Gunaratne, M. P. , Fette, L. , Burke, B. K. , & Runyon, M. (2021). Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina. medRxiv.
5. Musser, J. M. , Christensen, P. A. , Olsen, R. J. , Long, S. W. , Subedi, S. , Davis, J. J. , & Gollihar, J. D. (2021). Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. medRxiv.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献